Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. Using its proprietary switch-control kinase inhibitor platform and capabilities in kinase biology, Co. designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing medicines. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. Co. has developed a pipeline of drug candidates, including vimseltinib and DCC-3116. We show 28 historical shares outstanding datapoints in our DCPH shares outstanding history coverage, used to compute DCPH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DCPH market cap history over the course of time is important for investors
interested in comparing DCPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DCPH versus a peer is one thing; comparing
DCPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DCPH can fluctuate over the course of history.
With this page we aim to empower investors researching DCPH by allowing them to research the DCPH market cap history. |
Free DCPH Email Alerts:
Video: The Importance of Market Cap
